Knight Therapeutics (KHTRF) Projected to Post Earnings on Thursday

Knight Therapeutics (OTCMKTS:KHTRF) is expected to post its results before the market opens on Thursday, November 5th. Analysts expect Knight Therapeutics to announce earnings of $0.0098 per share and revenue of $90.74 million for the quarter.

Knight Therapeutics Price Performance

KHTRF remained flat at $8.13 during trading hours on Tuesday. The company had a trading volume of 3,600 shares, compared to its average volume of 7,054. The stock has a 50 day simple moving average of $7.44 and a 200-day simple moving average of $6.14. Knight Therapeutics has a 52-week low of $4.11 and a 52-week high of $8.31.

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada restated an “outperform” rating on shares of Knight Therapeutics in a research report on Friday, August 7th. One analyst has rated the stock with a Buy rating. According to MarketBeat, the stock has an average rating of “Buy”.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a Canadian specialty pharmaceutical company focused on acquiring, licensing, commercializing and, in some cases, developing innovative prescription medicines. The company seeks products that address unmet medical needs, with an emphasis on pharmaceuticals and therapies that can be introduced through regulatory and commercial expertise rather than broad internal research operations.

Knight markets and supports a portfolio of specialty medicines through direct commercial activities and partnerships.